Everist Announces Advance In Diagnosis, Prognosis Of Colorectal CancerEverist Genomics, a rapidly growing personalized medicine company, today announced the launch of the world's first comprehensive companion diagnostics and prognostics portfolio to improve early diagnosis, management and treatment of patients with colorectal cancer.
Everist Genomics Celebrates Origins, Future of Personalized MedicineEverist Genomics, a rapidly growing personalized medicine company, today announced that world-renowned scientist and genome sequencing pioneer J. Craig Venter will be the keynote speaker for its March 26th Gala Dinner at the Field Museum in Chicago.
Smartphone Tech Meets Personalized Medicine: Everist CardioDefenderEverist Genomics announced Friday that its executive vice chairman, Alex Charlton, will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference Monday in Munich, Germany.
Everist Genomics Discovers Genes Responsible for Recurrence of Colorectal CancerThe pharma startup Everist Genomics said Tuesday it had identified five specific genes and gene expression levels that lead to recurrence of colorectal cancer -- even when the cancer is caught at an early stage and surgically removed.
Everist Genomics to Launch CardioDefender, Advanced Mobile ECGThe medical device startup Everist Genomics Wednesday announced plans to commercialize its CardioDefender diagnostic system.
Ann Arbor's Everist Genomics Buys Angiologix Inc.Everest Genomics announced Monday it has completed the acquisition of 100 percent of the shares of Mountain View, Calif.-based Angiologix Inc., developer of the AngioDefender device for diagnosing heart and vein disease.
Ann Arbor's Everist Gets Federal OK For Cancer TestAnn Arbor-based Everist Genomics said Monday that it had received United States Clinical Laboratory Improvement Amendment certification to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk of cancer recurrence for patients with early stage colorectal cancer.
Everist Gets External Validation of Colorectal Cancer Risk TestAnn Arbor-based Everist Genomics, a company developing gene-based molecular assays for the prediction of cancer recurrence, last week announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test.
Genetics Squared Changes Name To Everist Genomics, Names New CEOAnn Arbor-based Genetics Squared, a company developing gene-based assays for the prediction of cancer recurrence, announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara as its new president and CEO, effective immediately. Its founder and former CEO will continue as CTO.